Health
Researchers develop ACE2 decoy to neutralise SARS-CoV-2 – Drug Target Review
Researchers have engineered human angiotensin converting enzyme 2 (hACE2) protein decoys that can protect cells from SARS-CoV-2.
Posted: 10 November 2020 | Hannah Balfour (Drug Target Review) | No comments yet
Using their de novo protein design strategy, researchers engineered human angiotensin converting enzyme 2 (hACE2) protein decoys that can protect cells from SARS-CoV-2 infection.
To infect cells within the respiratory tract, the Spike (S) protein on the surface of SARS-CoV-2 must bind to a receptor on human cells called angiotensin converting enzyme 2 (ACE2). The receptor binding domains (RBDs) are the section of the…
-
General19 hours agoInternal Revenue Service starts cutting 20,000 workers
-
Noosa News19 hours agoMan killed, woman seriously injured in collision in Wongabel, Atherton Tablelands, Queensland
-
Noosa News18 hours agoMoreton Bay oyster farm survives cyclone with help of wave wall innovation
-
Noosa News20 hours agoHelicopter pilots saving lives, providing food and fodder in flooded outback Queensland